Tolero Pharmaceuticals Inc. is using data from proof of mechanism studies to guide the go/no-go decisions for its pipeline of in-house and in-licensed cancer candidates. The platform-agnostic company expects to have its lead candidate in Phase I testing in 3Q13.

According to Chief Science Advisor David Bearss, the company's business model sets it apart from most other startups working in cancer.